Funded Tech Companies
Accropeutics
Headquartered in Suzhou, Jiangsu, Accropeutics has funding from Morningside Ventures and Shenzhen Capital.
Company Overview
Company Name
Accropeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Undisclosed
Suzhou, Jiangsu, Undisclosed
China
Suzhou, Jiangsu, Undisclosed
China
Phone
Website
Email Address
Company Background Information
Overview
Accropeutics has developed a robust portfolio of innovative compounds spanning from lead optimization to clinical trials. The company's RIPK1 inhibitor AC-003 has completed the Phase I clinical trial in China and the United States in August 2023 and achieved positive results, and the clinical trial for aGvHD patients is currently undergoing. The Company's RlPK2 inhibitor AC-101 has completed the Phase I clinical trial in Australia demonstrating an outstanding safety and PK/PD profile. AC-201, a selective TYK2/JAK1 inhibitor with "Pipeline-in-a-Product" potential for treating inflammatory and autoimmune diseases, has completed the Phase I trial in Australia and China, and is currently in Phase II clinical trial for patients with moderate to severe plaque psoriasis. The Company has multiple compounds in the PCC and preclinical research stages. The Company owns global rights of all its assets with more than 10 patents issued in major markets including the US, the EU, China, Japan, and Kor
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
3/14/2025
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Xiaohu Zhang
Company Investors
Browse more funded tech companies:
Accretive Health | Accrue Savings
Share this article
About Our VC Funding Database
This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.
Additional Resources for Entrepreneurs